Atezolizumab [TECENTRIQ]

DRUG3 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc.

Conditions

LymphomaNeoplasmsUrothelial Carcinoma

Phase 1

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

CompletedNCT01688206

Hoffmann-La RocheNeoplasms

Start: 2012-10-31End: 2018-03-12Updated: 2018-10-05

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

CompletedNCT02729896

Hoffmann-La RocheLymphoma

Start: 2016-11-09End: 2019-10-07Updated: 2020-12-23

Unknown Phase

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Genentech, Inc.Urothelial Carcinoma

Start: 2015-11-30End: 2016-08-31Updated: 2016-11-02

Related Papers

Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.

2022-02-188 citations

Abstract 1643: Leveraging tumor size and time to death from bevacizumab (BEV) historical data to predict overall survival in ovarian cancer patients treated with vanucizumab (VAN)

Cancer Research2018-07-012 citations

Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2018-05-201 citations

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study.

Journal of Clinical Oncology2017-05-201 citations

Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2016-05-2015 citations

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab.

Journal of Clinical Oncology2016-05-201 citations

Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.

Journal of Clinical Oncology2015-05-207 citations

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-2014 citations